A Phase 3 interventional study of collagenase clostridium histolyticum and Placebo in Dupuytren's Contracture, sponsored by Endo Pharmaceuticals. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-02.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing Microbial Collagenase in Dupuytren Contracture — none open to participants now, 1 under way, none of them phase 3. Microbial Collagenase · Dupuytren Contracture.
Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, this one is the 3rd largest by enrollment, is one of 2 that started in 2007, is one of 7 in phase 3, and was the 2nd registered.
78 studies on the registry are indexed under Dupuytren Contracture; 18 are open to participants now.
Browse Dupuytren Contracture studies →None of the 17 studies testing Microbial Collagenase in Dupuytren Contracture is open now. The open studies under Dupuytren Contracture, anywhere →
Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 12 Dupuytren Contracture studies recruiting now, 10 (83%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2007.
This study's enrollment of 308 is above the median of 72 across 57 interventional studies indexed under Dupuytren Contracture.
Median enrollment 76 across the 17 interventional studies. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
10 studies in Dupuytren Contracture by Keenova Therapeutics plc: none open now, none under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 10 studies in Dupuytren Contracture by Keenova Therapeutics plc, this one is one of 2 that started in 2007, is one of 3 in phase 3, and was the 1st registered.
Keenova Therapeutics plc’s Dupuytren Contracture studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keenova Therapeutics plc’s 10 in Dupuytren Contracture:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a Phase 3, double-blind, randomized, placebo-controlled study conducted in the United States. Subjects with a diagnosis of Dupuytren's contracture in a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint that resulted in a fixed flexion deformity of at least one finger, other than the thumb, that was at least 20° as measured by finger goniometry and was suitable for injection were randomized 2:1 to receive AA4500 0.58 mg or placebo.
This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 (NCT00528606) and AUX-CC-859 (NCT00533273)) and 7 non-pivotal studies were evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: collagenase clostridium histolyticum
Biological: Placebo
Subjects could have received up to three injections of AA4500 into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
Also known as: XIAFLEX®, AA4500
Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection
The Primary Outcome Measure for patients treated with AA4500 is the percentage of joints that were successfully treated where "successfully treated" was defined as reduction in contracture to within 0-5° of normal within 30 days of injection. The Primary Outcome Measure for placebo treated patients is the percentage of joints that were successfully treated where "successfully treated" was defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
Time frame: Within 30 days after the last injection
Clinical Improvement After the Last Injection
Clinical Improvement is defined as \>= 50% reduction from baseline in degree of contracture within 30 days of the injection.
Time frame: Baseline; within 30 days after the last injection
Percent Reduction From Baseline Contracture After the Last Injection
Percent change in degree of contracture measured as 100\* (baseline contracture - last available post-injection contracture)/baseline contracture.
Time frame: Baseline; within 30 days after the last injection
Change From Baseline Range of Motion After the Last Injection
Change in degree of motion measured as last available post-injection range of motion - baseline range of motion.
Time frame: Baselin; within 30 days after the last injection
Time to First Achieve Success After the Last Injection
Time frame: Last evaluation visit on which clinical success is achieved through the Day 30 evaluation
Clinical Success (Reduction in Contracture to 5° or Less) After the First Injection
Clinical Success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection.
Time frame: Within 30 days after first injection
Clinical Improvement After the First Injection
Clinical Improvement is defined as \>= 50% reduction from contracture within 30 days of the first injectionor greater of baseline contracture within 30 days of the injection.
Time frame: Baseline; within 30 days after the first injection
Percent Reduction From Baseline Contracture After the First Injection
Percent change in degree of contracture measured as 100\* (baseline contracture - last available post-injection contracture)/baseline contracture.
Time frame: Baseline, within 30 days after the first injection
Change From Baseline Range of Motion After the First Injection
Change in degree of motion measured as last available post-injection range of motion - baseline range of motion.
Time frame: Baseline; within 30 days after the first injection
| Milestone | AA4500 0.58 mg | Placebo |
|---|---|---|
| Started | 204 | 104 |
| Completed | 191 | 100 |
| Not completed | 13 | 4 |
| Withdrew: Withdrew consent | 4 | 3 |
| Withdrew: Lost to follow-up | 4 | 1 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Other | 2 | 0 |
The Primary Outcome Measure for patients treated with AA4500 is the percentage of joints that were successfully treated where "successfully treated" was defined as reduction in contracture to within 0-5° of normal within 30 days of injection. The Primary Outcome Measure for placebo treated patients is the percentage of joints that were successfully treated where "successfully treated" was defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
| Percentage of Joints | AA4500 0.58 mg | Placebo |
|---|---|---|
| Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection | 64 | 6.8 |
Clinical Improvement is defined as \>= 50% reduction from baseline in degree of contracture within 30 days of the injection.
| Percentage of Joints | AA4500 0.58 mg | Placebo |
|---|---|---|
| Clinical Improvement After the Last Injection | 84.7 | 11.7 |
Percent change in degree of contracture measured as 100\* (baseline contracture - last available post-injection contracture)/baseline contracture.
| Percent reduction from baseline | AA4500 0.58 mg | Placebo |
|---|---|---|
| Percent Reduction From Baseline Contracture After the Last Injection | 79.3 ± 32.58 | 8.6 ± 30.78 |
Change in degree of motion measured as last available post-injection range of motion - baseline range of motion.
| degrees | AA4500 0.58 mg | Placebo |
|---|---|---|
| Change From Baseline Range of Motion After the Last Injection | 36.70 ± 21.01 | 4.0 ± 14.77 |
| percentage of joints | AA4500 0.58 mg | Placebo |
|---|---|---|
| Injection 1, Day 1 | 12.8 | 0.0 |
| Injection 1, Day 7 | 12.3 | 0.0 |
| Injection 1, Day 30 | 14.3 | 1.0 |
| Injection 2, Day 0 | 0.5 | 0.0 |
| Injection 2, Day 1 | 4.9 | 0.0 |
| Injection 2, Day 7 | 5.4 | 0.0 |
| Injection 2, Day 30 | 6.4 | 1.0 |
| Injection 3, Day 0 | 0.0 | 0.0 |
| Injection 3, Day 1 | 2.0 | 0.0 |
| Injection 3, Day 7 | 2.5 | 0.0 |
| Injection 3, Day 30 | 2.5 | 4.9 |
| Day 90 | 0.5 | 0.0 |
| Did not reach clinical success by last injection | 36.0 | 93.2 |
Clinical Success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection.
| Percentage of Joints | AA4500 0.58 mg | Placebo |
|---|---|---|
| Clinical Success (Reduction in Contracture to 5° or Less) After the First Injection | 38.9 | 1.0 |
Clinical Improvement is defined as \>= 50% reduction from contracture within 30 days of the first injectionor greater of baseline contracture within 30 days of the injection.
| Percentage of Joints | AA4500 0.58 mg | Placebo |
|---|---|---|
| Clinical Improvement After the First Injection | 67.5 | 2.9 |
Percent change in degree of contracture measured as 100\* (baseline contracture - last available post-injection contracture)/baseline contracture.
| Percent reduction from baseline | AA4500 0.58 mg | Placebo |
|---|---|---|
| Percent Reduction From Baseline Contracture After the First Injection | 64.8 ± 34.60 | 4.7 ± 20.81 |
Change in degree of motion measured as last available post-injection range of motion - baseline range of motion.
| degrees | AA4500 0.58 mg | Placebo |
|---|---|---|
| Change From Baseline Range of Motion After the First Injection | 28.30 ± 20.23 | 1.50 ± 11.03 |
Collected over Non-serious adverse events (non-SAEs) were collected from time of study drug administration, serious adverse events (SAEs) were collected from time subject signed ICF. Non-SAEs & SAEs were collected until 30 days after completion or discharge from study.. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AA4500 0.58 mg | — | 8/204 (3.9%) | 196/204 (96.1%) |
| Placebo | — | 1/104 (1%) | 25/104 (24%) |
| Event | AA4500 0.58 mg | Placebo |
|---|---|---|
| Tendon ruptureInjury, poisoning and procedural complications | 2/204 | 0/104 |
| Acute cholecystitisHepatobiliary disorders | 0/204 | 1/104 |
| Complex regional pain syndromeNervous system disorders | 1/204 | 0/104 |
| Ligament disorderMusculoskeletal and connective tissue disorders | 1/204 | 0/104 |
| Myocardial infarctionCardiac disorders | 1/204 | 0/104 |
| Panic attackPsychiatric disorders | 1/204 | 0/104 |
| Pelvi-ureteric obstructionRenal and urinary disorders | 1/204 | 0/104 |
| Spinal fusion surgerySurgical and medical procedures | 1/204 | 0/104 |
| Event | AA4500 0.58 mg | Placebo |
|---|---|---|
| Oedema peripheralGeneral disorders | 148/204 | 4/104 |
| ContusionInjury, poisoning and procedural complications | 104/204 | 2/104 |
| Injection site haemorrhageGeneral disorders | 76/204 | 4/104 |
| Injection site painGeneral disorders | 66/204 | 5/104 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 65/204 | 3/104 |
| TendernessGeneral disorders | 54/204 | 0/104 |
| EcchymosisSkin and subcutaneous tissue disorders | 51/204 | 1/104 |
| Injection site swellingGeneral disorders | 43/204 | 4/104 |
| PruritusSkin and subcutaneous tissue disorders | 22/204 | 1/104 |
| Skin lacerationInjury, poisoning and procedural complications | 22/204 | 0/104 |
| Age, Categorical(Participants) | AA4500 0.58 mg | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 120 | 57 | 177 |
| >=65 years | 84 | 47 | 131 |
| Age, Continuous(years) | AA4500 0.58 mg | Placebo | Total |
|---|---|---|---|
| Mean | 62.3 ± 9.7 | 63.3 ± 9.1 | 62.7 ± 9.5 |
| Sex: Female, Male(Participants) | AA4500 0.58 mg | Placebo | Total |
|---|---|---|---|
| Female | 33 | 30 | 63 |
| Male | 171 | 74 | 245 |
| Race/Ethnicity, Customized(participants) | AA4500 0.58 mg | Placebo | Total |
|---|---|---|---|
| White | 203 | 104 | 307 |
| Hispanic | 1 | 0 | 1 |
| Region of Enrollment(participants) | AA4500 0.58 mg | Placebo | Total |
|---|---|---|---|
| United States | 204 | 104 | 308 |
Ran from Aug 2007 to primary completion in Apr 2008, 8 months.
Results were first posted in Oct 2010, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase